Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr. Thompson on Challenges Facing the Field of Multiple Myeloma

January 17th 2017

Michael A. Thompson, MD, PhD, medical director, precision medicine, Vince Lombardi Cancer Clinic, Aurora Health Care, discusses some of the challenges facing the field of multiple myeloma.

Dr. Usmani on Importance of CASTOR/POLLUX Trials in Myeloma

January 14th 2017

Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses the importance of the CASTOR and POLLUX trials for the treatment of patients with multiple myeloma.

Dr. Kelly on Racial Disparities in Multiple Myeloma

January 13th 2017

Kevin R. Kelly, MD, PhD, associate professor of Medicine, Keck School of Medicine, discusses a study examining racial disparities in patients with multiple myeloma.

Dr. Landgren on Questions After POLLUX and CASTOR Studies in Myeloma

January 6th 2017

C. Ola Landgren, MD, PhD, chief of Myeloma Service at Memorial Sloan Kettering Cancer Center, discusses unanswered questions following the results of the phase III POLLUX and CASTOR studies, which explored the addition of daratumumab (Darzalex) to lenalidomide (Revlimid) and dexamethasone or bortezomib (Velcade) and dexamethasone, respectively.

Transplant Remains Pivotal in Myeloma, Other Hematologic Cancers

January 2nd 2017

The use of stem cell transplantation has changed over the last few years, with the emergence of novel therapies and treatment strategies. But even with the FDA approvals of new agents for multiple myeloma and select lymphomas, transplant remains to be a curative and reliable strategy.

Myeloma Expert Highlights Practice-Changing ASH Findings

December 29th 2016

The landscape of multiple myeloma continues to shift with more drug approvals, but pivotal results out of the 2016 ASH Annual Meeting will likely alter it even further.

Dr. Kumar on the Rationale for Studying Venetoclax in Multiple Myeloma

December 26th 2016

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the rationale for investigating venetoclax as a treatment for patients with multiple myeloma.

Venetoclax Active in Heavily Treated Multiple Myeloma

December 21st 2016

The BCL-2 inhibitor venetoclax (Venclexta) demonstrated activity in one-fifth of patients with heavily pretreated multiple myeloma.

Benefits of Daratumumab Triplets in Myeloma Sustained With Longer Follow-Up

December 20th 2016

The benefits of 2 FDA-approved daratumumab–based triplet regimens were sustained in long-term data from 2 pivotal phase III studies presented at the 2016 ASH Annual Meeting.

Gene Expression Studies Offer Insight Into Myeloma Regimen's Efficacy

December 19th 2016

An analysis of c-MYC expression in relapsed myeloma identified subgroups of patients with improved response to the combination of an immunomodulator and a proteasome inhibitor.

Dual Transplant Prevails in Patients With Newly Diagnosed Myeloma

December 19th 2016

Patients with newly diagnosed multiple myeloma had significant improvement in progression-free survival when treated with dual versus single autologous stem-cell transplant.

Addition of Daratumumab Triples Increase in MRD Conversion in Relapsed Myeloma

December 16th 2016

The addition of daratumumab to standard-of-care regimens tripled the increase in conversion to negative minimal residual disease status in the treatment of patients with relapsed/refractory multiple myeloma.

Previously Treated Myeloma: Making Sense of Plethora of New Options

December 12th 2016

Multiple myeloma has seen significant treatment advances over the past decade. In 2015 alone, the FDA approved 5 new agents or regimens for previously treated patients.

Elotuzumab Triplet Yields High Response Rate in High-Risk Smoldering MM

December 12th 2016

The combination of elotuzumab, lenalidomide, and dexamethasone has excellent activity and is well-tolerated in the treatment of high-risk smoldering multiple myeloma (SMM), providing hope that it can delay or even halt progression to MM.

Multiple Myeloma Transplant Trial Shows No Extra Benefit with Additions to Standard Therapy

December 8th 2016

According to the results of the phase III StaMINA trial evaluating posttransplant therapy in multiple myeloma, a second a round of chemotherapy or stem cell transplant does not improve progression-free survival or overall survival compared with the current standard course of treatment alone.

Dr. Jackson on Lenalidomide as a Highly-Effective Maintenance Therapy in Myeloma

December 7th 2016

Graham Jackson, MD, PhD, Northern Institute for Cancer Research, Newcastle University, discusses results of a study that determined lenalidomide (Revlimid) is a highly-effective maintenance therapy in myeloma patients of all ages.

Subcutaneous Daratumumab Safe, Effective in Myeloma

December 6th 2016

Subcutaneous delivery of daratumumab was well tolerated with comparable efficacy to the FDA-approved intravenous dose in patients with relapsed/refractory multiple myeloma.

Venetoclax Highly Effective With Bortezomib/Dexamethasone for Multiple Myeloma

December 6th 2016

Adding venetoclax to bortezomib and dexamethasone showed very promising efficacy and acceptable safety for patients with relapsed/refractory multiple myeloma.

Selinexor Active in Heavily Pretreated Myeloma

December 6th 2016

Selinexor, in combination with dexamethasone, induced a response rate of 20.5% (n = 16) among 78 heavily pretreated patients with relapsed/refractory multiple myeloma, according to results from the phase IIb STORM trial presented at the 2016 ASH Annual Meeting.

Pembrolizumab Combo Highly Effective for Heavily Pretreated Myeloma

December 5th 2016

Treatment with the combination of pembrolizumab, pomalidomide, and dexamethasone demonstrated promising durable efficacy and a tolerable safety profile for patients with relapsed/refractory multiple myeloma.